PAPPA2 and non-small cell lung carcinoma: Among all patients in the NSCLC set, those with TMB‐H or PAPPA2‐Mut (53/165) achieved significantly longer PFS (HR, 0.36 [95% CI, 0.23–0.57]; p < 0.001; Figure 4H) than counterparts.